The active ingredient, tirzepatide, engages two receptors, GIP and GLP-1. These are the receptors for two hormones the digestive system produces after eating, hormones that influence appetite and blood sugar. For people in the Philadelphia area, it is the medication behind Bodi Envi's Personalized Compounded Tirzepatide Weight-Management Programs.
In a compounded program, a licensed compounding pharmacy prepares the medication for a specific patient after a licensed provider has written the prescription. The provider sets the weekly injection schedule, picks the starting dose and decides whether and when it changes.
Compounded medications sit outside FDA approval. Personalized Compounded Tirzepatide is not FDA-approved, is not equivalent to Mounjaro® and Zepbound®, and is not reviewed by the FDA for safety, effectiveness or quality before it is marketed. That is why each prescription rests on a licensed provider's individual judgement. Brand names are trademarks of their respective owners. Compounding pharmacies are regulated by state boards of pharmacy for sterile compounding and are required to follow United States Pharmacopeia standards.